Oncological outcomes of primary renal malignancies other than clear cell renal carcinoma: A retrospective study from a tertiary center

AbstractIntroductionA lot of research is available about clear cell renal carcinomas (ccRCC). But there are lesser known facts about other subtypes of renal malignancies. With advances in immunohistochemical and cytogenetic techniques, new variants of renal tumors are being increasingly reported. The treatment and prognosis of such rare malignancies is still an enigma. We performed this study to analyze the incidence, clinico-pathological features, surgical treatment, and survival of non-clear cell RCC at our institution.Materials and MethodsThe histopathological reports of 77 Nephrectomy specimens who underwent surgical treatment for suspected renal tumors from 2013-2018 were retrospectively reviewed. 19 (24%) of patients had documented uncommon histologic variants of RCC. The clinical, demographic, and histologic characteristics of these patients were analyzed, and survival was evaluated. The characteristic light microscopy and immunohistochemical features of these lesions were documented.ResultsMean age was 45 years (21-67 years). Out of 19 patients, 14 (73.6%) were males, and 5 (26.4%) were females. Mean tumor size was 12 (6-31) cm in the largest dimension. 17 (22%) patients underwent radical nephrectomy, and 2 (2.5%) were treated with partial nephrectomy. Patients with collecting duct, synovial sarcoma, and primitive neuro-ectodermal tumor (PNET) had associated inferior vena caval thrombus and underwent venous thrombectomy. Adjuvant treatment in the form of chemotherapy was instituted in collecting duct, adult Wilms and pure sarcomas. There was no mortality in the papillary carcinoma, and the worst prognosis was encountered inConclusionSarcomatoid and collecting duct variants were associated with worse prognosis. Presently, aggressive surgical extirpation is the mainstay in the management of these histologic variants. Adjuvant chemotherapy and TKI inhibitors have a limited role.

Download Full-text

Comprehensive Immunoprofiles of Renal Cell Carcinoma Subtypes

Cancers ◽

10.3390/cancers12030602 ◽

2020 ◽

Vol 12 (3) ◽

pp. 602 ◽

Cited By ~ 3

Author(s):

Moonsik Kim ◽

Jin Woo Joo ◽

Seok Joo Lee ◽

Yoon Ah Cho ◽

Cheol Keun Park ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Clear Cell ◽

Collecting Duct ◽

Cathepsin K ◽

Renal Tumors ◽

Duct Carcinoma ◽

Epithelial Tumors ◽

Papillary Type

In recent years, renal epithelial tumors have been among the fastest reclassifying tumors, requiring updates to the tumor classification system. Nonetheless, immunohistochemistry (IHC) remains the most widely used tool for renal epithelial tumors. In this proposal, we aimed to create the most efficient IHC panel for categorizing the diverse subtypes of renal tumors, and to find out more specific immunohistochemical results in each subtype or each antibody. A total of 214 renal tumors were analyzed using 10 possible IHC markers to differentiate subtypes, including three major renal cell carcinoma (RCC) subtypes, clear-cell type (50 cases), papillary type (50 cases), and chromophobe type (20 cases), and minor subtypes (MiT RCC, 13 cases; collecting duct carcinoma, 5 cases; and oncocytoma, 10 cases). A triple immunomarker (cytokeratin 7 (CK7)-carbonic anhydrase IX (CAIX)- alpha-methylacyl-CoA racemase (AMACR)) panel is useful in particular high-grade clear-cell tumors. If IHC remains ambiguous, the use of an adjunctive panel can be suggested, including CD10, epithelial membrane antigen, cathepsin K, c-kit, hepatocyte nuclear factor 1-β, and E-cadherin. For an efficient immunohistochemical strategy for subtyping of RCC, we conclude that the CK7-CAIX-AMACR panel is the best primary choice for screening subtyping.

Download Full-text

Expression and role of adrenomedullin in renal tumors and value of its mRNA levels as prognostic factor in clear-cell renal carcinoma

International Journal of Cancer ◽

10.1002/ijc.24568 ◽

2009 ◽

Vol 125 (10) ◽

pp. 2307-2315 ◽

Cited By ~ 18

Author(s):

Jean-Laurent Deville ◽

Catherine Bartoli ◽

Caroline Berenguer ◽

Samantha Fernandez-Sauze ◽

Itidal Kaafarani ◽

...

Keyword(s):

Prognostic Factor ◽

Renal Carcinoma ◽

Clear Cell ◽

Renal Tumors ◽

Mrna Levels ◽

Clear Cell Renal Carcinoma ◽

Cell Renal Carcinoma

Download Full-text

Clear - cell renal carcinoma: review of literature in pediatric population / Carcinoma renal de células-claras: revisão bibliográfica na população pediátrica

Arquivos Médicos dos Hospitais e da Faculdade de Ciências Médicas da Santa Casa de São Paulo ◽

10.26432/1809-3019.2020.65.017 ◽

2020 ◽

Vol 65 (1) ◽

pp. 1

Author(s):

Fernanda Monteiro Orellana ◽

Pablo Leonardo Traete ◽

Victor Notari de Campos ◽

Alan Rechamberg Ziroldo ◽

Luis Gustavo Morato de Toledo

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Renal Carcinoma ◽

Clear Cell ◽

Pediatric Population ◽

Renal Tumors ◽

Clear Cell Renal Carcinoma ◽

Pubmed Database ◽

Cell Renal Carcinoma

ABSTRACT:Introduction: The first reports of renal tumors originated from the renal tubule epithelium date from 1855, Robin, and 1867, Waldeyer. However, at the same era, some pathologists wrong believed these tumors were originated from adrenal gland tissues due to the fat content of the tumor (hypernephroid tumor theory - origin above the kidney, 1894). The first diagnostic test for renal tumor was excretory urography. Over the years, with the emergence of ultrasonography (US), it has been replaced. Nowadays, after the US screening, all renal lesions should be evaluated, in a complementary way, with computed tomography (CT) - gold standard - in the pre-contrast, arterial, portal, nephrographic phases. This is necessary to characterize the presence of enhancement after contrast. A kidney injury that enhances more than 15 Housfield units (UH) is suspected of kidney cell cancer. There are different subtypes of renal tumors derived from various sites of the nephron. Clear cell Renal Cell Carcinoma (RCC) is one of the subtypes that originates from the renal cortex. It is a rare tumor in children. Objective: The aim of this chapter is to review de incidence, pathology, diagnosis and treatment in clear-cell renal carcinoma in pediatric population. Methods: The authors performed a literary review about clear-cell renal carcinoma in pediatric population using Pubmed Database and Campbell-Walsh Urology as source search.Keywords: Renal cell carcinoma, Tumor, Pediatrics, Kidney, Nefrectomy ResumoRESUMO:Introdução: Os primeiros relatos de tumores renais originados do epitélio do túbulo renal datam de 1855, Robin, e 1867, Waldeyer. Contudo, na mesma época, alguns patologistas acreditavam erroneamente que esses tumores provinham dos tecidos das glândulas supra-renais, devido ao teor de gordura do tumor (hypernephroid tumor theory – origem acima do rim, 1894). O primeiro teste diagnóstico para tumor renal foi a urografia excretora. Ao longo dos anos, com o surgimento da ultrassonografia, esse teste foi substituído. Atualmente, após a leitura da ultrassonografia, todas as lesões renais devem ser avaliadas, de forma complementar, com tomografia computadorizada (TC) – padrão ouro – nas fases pré-contraste, arterial, porta e nefrográfica. Isso é necessário para caracterizar a presença de melhora após contraste. Uma lesão renal que aumenta mais de 15 unidades Housfield (UH) é suspeita de câncer de células renais. Existem diferentes subtipos de tumores derivados de vários locais do néfron. O carcinoma de células renais de células claras (CCR) é um dos subtipos originários do córtex renal. É um tumor raro em crianças. Objetivo: O objetivo deste capítulo é revisar a incidência, a patologia, o diagnóstico e o tratamento do CCR na população pediátrica. Método: Os autores realizaram uma revisão literária sobre carcinoma renal de células claras em população pediátrica usando a base de dados PubMed e o livro Campbell-Walsh de Urologia como fonte de pesquisa.Palavras chave: Carcinoma de células renais, Tumor, Pediatria, Rim, Nefrectomia

Download Full-text

CLEAR CELL HISTOLOGY REPRESENTS WORSE PROGNOSIS IN PATIENTS UNDERGOING SURGICAL TREATMENT FOR RENAL CELL CARCINOMA

The Journal of Urology ◽

10.1016/s0022-5347(09)61008-9 ◽

2009 ◽

Vol 181 (4S) ◽

pp. 355-356

Author(s):

Patrick E Teloken ◽

R Houston Thompson ◽

Satish K Tickoo ◽

Angel M Cronin ◽

Caroline J Savage ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Surgical Treatment ◽

Cell Carcinoma ◽

Renal Cell ◽

Clear Cell ◽

Worse Prognosis

Download Full-text

miRNA profiling in renal carcinoma suggest the existence of a group of pro-angionenic tumors in localized clear cell renal carcinoma

10.1101/2019.12.12.19014696 ◽

2019 ◽

Author(s):

Lucía Trilla-Fuertes ◽

Natalia Miranda ◽

Daniel Castellano ◽

Rocío López-Vacas ◽

Carlos A. Farfán Tello ◽

...

Keyword(s):

Cell Carcinoma ◽

Renal Carcinoma ◽

Clear Cell ◽

Expression Profiles ◽

Specific Treatment ◽

Renal Tumors ◽

Clear Cell Renal Carcinoma ◽

Mirna Expression Profiles ◽

Cell Renal Carcinoma ◽

Antiangiogenic Drugs

AbstractRenal cell carcinoma comprises a variety of entities, the most common being the clear-cell, papillary and chromophobe subtypes. These subtypes are related to different clinical evolution; however, most therapies have been developed for clear-cell carcinoma and there is not a specific treatment based on different subtypes. In this study, one hundred and sixty-four paraffin samples from primary nephrectomies for localized tumors were analyzed. MiRNAs were isolated and measured by microRNA arrays. Significance Analysis of Microarrays and Consensus Cluster algorithm were used to characterize different renal subtypes. The analyses showed that chromophobe renal tumors are a homogeneous group characterized by an overexpression of miR 1229, miR 10a, miR 182, miR 1208, miR 222, miR 221, miR 891b, miR 629-5p and miR 221-5p. On the other hand, clear cell renal carcinomas presented two different groups inside this histological subtype, with differences in miRNAs that regulate focal adhesion, transcription, apoptosis and angiogenesis processes. Specifically, one of the defined groups had an overexpression of proangiogenic microRNAs miR185, miR126 and miR130a. In conclusion, differences in miRNA expression profiles between histological renal subtypes were established. In addition, clear cell renal carcinomas had different expression of proangiogenic miRNAs. With the emergence of antiangiogenic drugs, these differences could be used as therapeutic targets in the future or as a selection method for tailoring personalized treatments.

Download Full-text

1651: Molecular Prognostic Modeling Using Protein Expression Profile in Clear Cell Renal Carcinoma

The Journal of Urology ◽

10.1016/s0022-5347(18)38859-1 ◽

2004 ◽

Vol 171 (4S) ◽

pp. 436-436 ◽

Cited By ~ 3

Author(s):

Hyung L. Kim ◽

David B. Seligson ◽

Nicolette Janzen ◽

Matthew H. Bui ◽

Robert A. Figlin ◽

...

Keyword(s):

Protein Expression ◽

Expression Profile ◽

Renal Carcinoma ◽

Clear Cell ◽

Clear Cell Renal Carcinoma ◽

Protein Expression Profile ◽

Cell Renal Carcinoma ◽

Prognostic Modeling

Download Full-text

Delayed Pancreatic Metastasis of Renal Clear Cell Carcinoma

Acta Chirurgica Latviensis ◽

10.2478/chilat-2014-0016 ◽

2013 ◽

Vol 13 (2) ◽

pp. 79-80

Author(s):

Zane Simtniece ◽

Gatis Kirsakmens ◽

Ilze Strumfa ◽

Andrejs Vanags ◽

Maris Pavars ◽

...

Keyword(s):

Abdominal Pain ◽

Surgical Treatment ◽

Cell Carcinoma ◽

Clear Cell ◽

Clear Cell Carcinoma ◽

Primary Tumour ◽

Renal Clear Cell Carcinoma ◽

Pancreatic Metastasis ◽

Distal Pancreatic Resection

Abstract Here, we report surgical treatment of a patient presenting with pancreatic metastasis (MTS) of renal clear cell carcinoma (RCC) 11 years after nephrectomy. RCC is one of few cancers that metastasise in pancreas. Jaundice, abdominal pain or gastrointestinal bleeding can develop; however, asymptomatic MTS can be discovered by follow-up after removal of the primary tumour. The patient, 67-year-old female was radiologically diagnosed with a clinically silent mass in the pancreatic body and underwent distal pancreatic resection. The postoperative period was smooth. Four months after the surgery, there were no signs of disease progression.

Download Full-text

Clear cell histology portends a worse prognosis than other WHO grade II histologies

Journal of Neuro-Oncology ◽

10.1007/s11060-020-03668-5 ◽

2021 ◽

Author(s):

Pranay Soni ◽

Jianning Shao ◽

Arbaz Momin ◽

Diana Lopez ◽

Lilyana Angelov ◽

...

Keyword(s):

Clear Cell ◽

Who Grade ◽

Grade Ii ◽

Worse Prognosis

Download Full-text

Renal angiomyoadenomatous tumor (RAT): a rare distinct entity with diagnostic challenges—a case report

Journal of the Egyptian National Cancer Institute ◽

10.1186/s43046-020-00056-y ◽

2021 ◽

Vol 33 (1) ◽

Author(s):

Ankur Majumder ◽

Ravi Hari Phulware ◽

Arvind Ahuja ◽

Anurag Singla ◽

Pawan Kumar

Keyword(s):

Cell Carcinoma ◽

Clear Cell ◽

Clear Cell Carcinoma ◽

Close Association ◽

Good Prognosis ◽

Renal Tumors ◽

Team Approach ◽

Renal Neoplasm ◽

Presenting Symptoms ◽

Long Term Follow Up

Abstract Background Renal angiomyoadenomatous tumor (RAT) is a recently described rare renal neoplasm with variations in the presentation, gross, and microscopic findings, and having a benign course and good prognosis. It is characterized microscopically by the admixture of three components—epithelial cells arranged in tubules and nests, angiomyomatous stroma, and capillary-sized interconnecting vascular channels in close association with the epithelial cell clusters. Microscopically, these tumors can be confused with clear cell carcinoma, papillary carcinoma, mixed epithelial and stromal tumors, and angiomyolipoma. RAT differs from conventional clear cell carcinomas, which can rarely be associated with an identical leiomyomatosis stroma occasionally forming abortive vascular structures. RAT is a distinct morphologic entity, being different morphologically, immunohistochemically, and genetically from all renal tumors including conventional clear cell carcinoma and mixed epithelial and stromal tumor of the kidney. Case presentation Here, we report a case of a 21-year-old man with renal angiomyoadenomatous tumor, a rare neoplasm with only a few previous cases reported in the literature. Unlike our case, most tumors have been identified in middle-aged males; they present as well-circumscribed, encapsulated tan-brown masses with variably prominent cystic areas. Conclusion Diagnosis of RAT is challenging because of the rarity of the disease and common presenting symptoms to other renal pathology and is supplemented with histopathology and immunohistochemistry. A multidisciplinary team approach for diagnosis and management along with long-term follow-up are warranted.

Download Full-text